Chronix Biomedical, Inc.
is a molecular diagnostics company creating laboratory developed blood
tests, that are designed for therapy monitoring for patients with
chemotherapy or immunotherapy and for relapse monitoring after tumor
All Chronix tests are blood tests (Liquid biopsy tests) which detect tumor-derived cell-free DNA in blood samples of patients. Gains and losses of large chromosome sections that are present in the genome of cancer cells are detected and combined in a comprehensive copy number instability (CNI) score that can indicate tumor existance, remission or progression. Chronix blood tests are suitable for therapy monitoring for patients with chemotherapy or immunotherapy and for relapse monitoring after tumor resection (CNI MONITOR).
A blinded clinical trial conducted by Chronix Biomedical to study a group of patients undergoing cancer treatments showed, that the CNI MONITOR test is suitable for therapy monitoring for patients with chemotherapy or immunotherapy and for relapse monitoring after tumor resection- CNI MONITOR predicted outcome results 6-9 weeks earlier than radiography.
CNI score based predictions of a therapy failure were correct in 89% of times (positive predictive value, PPV) when based on the change from baseline to cycle 2. When data from another sample obtained prior to cycle 3 was included the prediction of progressive disease was correct in 100% of the cases.
In clinical practice conventional biochemical tumor markers are often used during therapy to assess drug efficacy. When compared to the early prediction of outcome gained by CNI score, a highly significant lower accuracy was found.
Advantages of this new technology, are that we can now look at the entirety of the body and its health state relating to cancer. Current scanning and tissue biopsy can only look at a specific part of the body, such as the lung or prostate, and is usually only carried out on presentation of symptoms.
Chronix Biomedical reports a positive interim analysis of its ongoing validation study of its Copy Number Instability (CNI)-based therapeutic monitoring test in pancreatic cancer.
The study compares the accuracy of Chronix’s CNI-based test at predicting a clinical response, as early as after the first cycle of chemotherapy compared to CA19-9, a commonly used biomarker.
Study finds CNI score to be a stronger predictor of time to recurrence in head and neck cancer than current method based on lymph node invasion. The study enrolled 54 patients undergoing surgery for this cancer type and evaluated the Chronix test as a predictor of time to progression in comparison with the current method based on the degree of tumour invasion of lymph nodes (pN status).
This is the third year that Chronix is presenting its study results at ASCO — this year’s results are from a blinded prospective study validating the use of a CNI Monitor blood test to predict the treatment outcome of patients undergoing immunotherapy.
“The knowledge that we have gained over the past year now suggests to us that we are able to provide to doctors and their patients the ability to diagnose at the most earliest stage the presence of cancer in their body.”
Howard Urnovitz, CEO of Chronix Biomedical for The Times
“We believe our cancer blood tests will lead to a world where no one dies unnecessarily of cancer.”